within Pharmacolibrary.Drugs.ATC.N;

model N07XX06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0006616666666666667,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00752,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor, primarily used in the treatment of chorea associated with Huntington's disease. It reduces the amount of monoamines (such as dopamine, serotonin, norepinephrine) available in nerve terminals. Tetrabenazine is currently approved and in clinical use for this purpose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral doses.</p><h4>References</h4><ol><li><p>Roberts, MS, et al., &amp; Galloway, HM (1986). The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. <i>European journal of clinical pharmacology</i> 29(6) 703–708. DOI:<a href=\"https://doi.org/10.1007/BF00615962\">10.1007/BF00615962</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3709613/\">https://pubmed.ncbi.nlm.nih.gov/3709613</a></p></li><li><p>Mehvar, R, et al., &amp; Skelton, D (1987). Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 15(2) 250–255. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2882986/\">https://pubmed.ncbi.nlm.nih.gov/2882986</a></p></li><li><p>Heo, YA, &amp; Scott, LJ (2017). Deutetrabenazine: A Review in Chorea Associated with Huntington&#x27;s Disease. <i>Drugs</i> 77(17) 1857–1864. DOI:<a href=\"https://doi.org/10.1007/s40265-017-0831-0\">10.1007/s40265-017-0831-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29080203/\">https://pubmed.ncbi.nlm.nih.gov/29080203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX06;
